Aquestive therapeutics, inc. (AQST)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18
Cash flows from operating activities:
Net loss

-16,530

-12,636

-18,412

-20,472

-14,726

-13,944

-15,038

-36,493

4,099

Adjustments to reconcile net loss to net cash used for operating activities:
Depreciation and amortization

887

-

-

-

783

-

-

-

-

Depreciation and amortization

-

-

-

-

-

-

733

765

940

Change in fair value of warrant

-

-

-

-

-

0

4,116

1,859

-697

Share-based compensation

1,860

1,872

1,869

1,810

1,520

1,399

1,236

27,305

0

Asset retirement obligation accretion

-

-

-

-

-

-

33

35

34

Amortization of intangible

-

-

-

-

-

-

13

12

13

Amortization of debt issuance costs and discounts

584

591

557

392

389

399

374

465

458

Non-cash interest expense

0

335

-481

-22

527

-

-

-

-

All other non-cash expenses

144

-

-

-

45

-

-

-

-

Interest received other than in cash for example by issuing additional debt securities.

-

-

-

-

-

-

-

0

16

Amount of expense related to write-down of receivables to the amount expected to be collected. Includes, but is not limited to, accounts receivable and notes receivable and amount of direct write-downs of accounts receivable charged against the allowance.

-

-

-

-

-

-

-11

-8

39

Other, net

-

-

-

-

-

-

-

0

0

Changes in operating assets and liabilities:
Trade receivables and other receivables

-3,738

-

-

2,721

963

-

-

-2,820

3,301

Inventories, net

228

-1,265

-523

-490

-304

958

135

499

-165

Prepaid expenses and other current assets

-53

-

-

-

1,715

-

-

-

-

Prepaid expenses and other current assets

-

-

-

-

-

-

-

128

51

Accounts payable and accrued expenses

-3,575

-

-3,803

1,477

-3,306

-

-839

4,314

-721

Deferred revenue

-282

2,192

96

-239

-448

-60

-453

64

-177

Net cash used for operating activities

-13,637

-10,575

-14,789

-17,166

-17,680

-2,812

-11,475

511

785

Cash flows from investing activities:
Capital expenditures

131

86

91

110

376

490

448

627

259

Net cash used for investing activities

-131

-86

-91

-110

-376

-490

-448

-627

-259

Cash flows from financing activities:
Payments for deferred offering costs

-

-

-

-

-

-

3,167

111

1,417

Payments for taxes on share-based compensation

37

104

59

55

2,609

124

280

5,623

0

Net cash used for financing activities

-37

39,073

13,629

-493

-2,609

-81

65,267

-5,734

-1,417

Net decrease in cash and cash equivalents

-13,805

28,412

-1,251

-17,769

-20,665

-3,383

53,344

-5,850

-891

Supplemental disclosures of cash flow information:
Cash payments for interest

2,188

2,187

2,576

1,568

1,009

1,538

1,541

1,485

1,485

Increase (decrease) in future cash outflow to pay for purchases of fixed assets that have occurred.

84

-

-

-

253

-

-

-

-

Increase (decrease) in future cash outflow to pay for purchases of fixed assets that have occurred.

-

-

-

-

-

-

-

-

15

Increase (decrease) in future cash outflow to pay for deferred offering costs that have occurred.

0

-162

162

-311

311

-73

-2,209

1,694

0

Withholding tax payments accrued on share based compensation.

-1

0

0

4

-4

814

-40

1,741

0